

# COTA

## Make oncology research personalized with clinicogenomics data



### ABOUT COTA'S CLINICOGENOMICS PRODUCT

Augment deep clinical data with comprehensive genomic profiling, fueling your team's biomarker discovery and rapid drug development process.

COTA's clinicogenomics product covers:

- × Comprehensive genomic and transcriptomic profiling to identify established and novel biomarkers
- × Secondary analysis data (ie. BAM, VCF) and tertiary analysis summary file with key findings
- × All time points testing is performed, not just at baseline or diagnosis



### USE CASES

Information on emerging biomarkers can enable:

- × More accurate stratification of patients based on predictive response to therapies
- × Rapid development of next generation targeted and immunotherapies

### ABOUT COTA

Bringing clarity to cancer

Founded in 2011 by doctors, engineers and data scientists to create clarity from fragmented and often inaccessible real-world data. COTA curates fit-for-purpose, regulatory-grade oncology RWD from structured and unstructured EHR data that is used across the drug development lifecycle.

Our data is ready for analysis and contains clear longitudinal patient journeys that support regulatory submissions and research questions about treatment patterns, real-world outcomes, and comparisons.

**2M+** Cancers lives in our network

**1,500+** Oncologist across our network

**3** FDA and EMA approvals

### ONGOING RESEARCH PARTNERSHIPS WITH:

THE UNIVERSITY OF  
**CHICAGO**

**UTSouthwestern**  
Medical Center



[www.cotahealthcare.com](http://www.cotahealthcare.com)